Antibodies to Epstein‐Barr virus‐specific DNase in patients with nasopharyngeal carcinoma and control groups
Identifieur interne : 001711 ( Main/Merge ); précédent : 001710; suivant : 001712Antibodies to Epstein‐Barr virus‐specific DNase in patients with nasopharyngeal carcinoma and control groups
Auteurs : Jen-Yang Chen [République populaire de Chine] ; Chien-Jen Chen [République populaire de Chine] ; Mei-Ying Liu [République populaire de Chine] ; Show-Mei Cho [République populaire de Chine] ; Mow-Ming Hsu [République populaire de Chine] ; Tsong-Chou Lynn [République populaire de Chine] ; Ti Shieh [République populaire de Chine] ; Shieh-Mien Tu [République populaire de Chine] ; Hong-Hsin Lee [République populaire de Chine] ; Shiow-Ling Kuo [République populaire de Chine] ; Ming-Yang Lai [République populaire de Chine] ; Chang-Yao Hsieh [République populaire de Chine] ; Cheng-Po Hu [République populaire de Chine] ; Czau-Siung Yang [République populaire de Chine]Source :
- Journal of Medical Virology [ 0146-6615 ] ; 1987-09.
English descriptors
Abstract
Serum samples from 154 patients with nasopharyngeal carcinoma (NPC), 374 with other cancers, 1,000 normal controls from Government Employees' Clinic Center (GECC), and 3,642 individuals of various ethnic‐dialect groups living in high‐risk areas for NPC were collected and the concentration of antibodies to Epstein‐Barr virus (EBV)‐specific DNase activity was determined. Taking a serum sample where 1 ml will neutralize two or more units of the DNase activity as positive, 24 units as low level, 446 units as medium level, and more than 6 units as a high level of antibody, 90.3% of the NPC patients contained significant amounts of antibodies to EBV‐specific DNase activity and most of those had high levels of the antibody. In contrast, only 11% of sera from patients with cancers other than NPC contained antibodies to EBV‐specific DNase activity, and high levels were very rare (2.1%). The difference in positive rates between these two groups is highly significant according to the χ2 test (P < 0.001). The positive rate of this antibody in the control group (GECC) was 5.3% with 0.076, 0.8%, and 4.5% having high, medium, and low levels of antibodies, respectively. Again, the difference in positive rates between the GECC group and the NPC group is statistically significant (P < 0,001). Taken separately, the positive rates of anti‐EBV DNase activity in the three high‐risk groups were 11.7%, 13.0%, and 13.1%. No significant difference in age distribution for the levels of this antibody was observed in the control GECC group or the three high‐risk groups. However, the positive rates of the three high‐risk groups are more than twice those of the GECC group (11.7% ∼ 13.1% vs 5.3%). This ratio coincides with the ratio of the probability of developing NPC in high‐risk groups compared to that of the GECC group (also more than two times). The significance of this coincidence is discussed.
Url:
DOI: 10.1002/jmv.1890230103
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000C16
- to stream Istex, to step Curation: 000799
- to stream Istex, to step Checkpoint: 000E32
Links to Exploration step
ISTEX:583381D67BFE0CC46E820B7FFE789875F5469C2BLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Antibodies to Epstein‐Barr virus‐specific DNase in patients with nasopharyngeal carcinoma and control groups</title><author><name sortKey="Chen, Jen Ang" sort="Chen, Jen Ang" uniqKey="Chen J" first="Jen-Yang" last="Chen">Jen-Yang Chen</name></author><author><name sortKey="Chen, Chien En" sort="Chen, Chien En" uniqKey="Chen C" first="Chien-Jen" last="Chen">Chien-Jen Chen</name></author><author><name sortKey="Liu, Mei Ing" sort="Liu, Mei Ing" uniqKey="Liu M" first="Mei-Ying" last="Liu">Mei-Ying Liu</name></author><author><name sortKey="Cho, Show Ei" sort="Cho, Show Ei" uniqKey="Cho S" first="Show-Mei" last="Cho">Show-Mei Cho</name></author><author><name sortKey="Hsu, Mow Ing" sort="Hsu, Mow Ing" uniqKey="Hsu M" first="Mow-Ming" last="Hsu">Mow-Ming Hsu</name></author><author><name sortKey="Lynn, Tsong Hou" sort="Lynn, Tsong Hou" uniqKey="Lynn T" first="Tsong-Chou" last="Lynn">Tsong-Chou Lynn</name></author><author><name sortKey="Shieh, Ti" sort="Shieh, Ti" uniqKey="Shieh T" first="Ti" last="Shieh">Ti Shieh</name></author><author><name sortKey="Tu, Shieh Ien" sort="Tu, Shieh Ien" uniqKey="Tu S" first="Shieh-Mien" last="Tu">Shieh-Mien Tu</name></author><author><name sortKey="Lee, Hong Sin" sort="Lee, Hong Sin" uniqKey="Lee H" first="Hong-Hsin" last="Lee">Hong-Hsin Lee</name></author><author><name sortKey="Kuo, Shiow Ing" sort="Kuo, Shiow Ing" uniqKey="Kuo S" first="Shiow-Ling" last="Kuo">Shiow-Ling Kuo</name></author><author><name sortKey="Lai, Ming Ang" sort="Lai, Ming Ang" uniqKey="Lai M" first="Ming-Yang" last="Lai">Ming-Yang Lai</name></author><author><name sortKey="Hsieh, Chang Ao" sort="Hsieh, Chang Ao" uniqKey="Hsieh C" first="Chang-Yao" last="Hsieh">Chang-Yao Hsieh</name></author><author><name sortKey="Hu, Cheng O" sort="Hu, Cheng O" uniqKey="Hu C" first="Cheng-Po" last="Hu">Cheng-Po Hu</name></author><author><name sortKey="Yang, Czau Iung" sort="Yang, Czau Iung" uniqKey="Yang C" first="Czau-Siung" last="Yang">Czau-Siung Yang</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:583381D67BFE0CC46E820B7FFE789875F5469C2B</idno><date when="1987" year="1987">1987</date><idno type="doi">10.1002/jmv.1890230103</idno><idno type="url">https://api.istex.fr/document/583381D67BFE0CC46E820B7FFE789875F5469C2B/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000C16</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000C16</idno><idno type="wicri:Area/Istex/Curation">000799</idno><idno type="wicri:Area/Istex/Checkpoint">000E32</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000E32</idno><idno type="wicri:doubleKey">0146-6615:1987:Chen J:antibodies:to:epstein</idno><idno type="wicri:Area/Main/Merge">001711</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Antibodies to Epstein‐Barr virus‐specific DNase in patients with nasopharyngeal carcinoma and control groups</title><author><name sortKey="Chen, Jen Ang" sort="Chen, Jen Ang" uniqKey="Chen J" first="Jen-Yang" last="Chen">Jen-Yang Chen</name><affiliation wicri:level="1"><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Departments of Bacteriology, College of Medicine, National Taiwan, University, Taipei, Taiwan</wicri:regionArea><wicri:noRegion>Taiwan</wicri:noRegion></affiliation></author><author><name sortKey="Chen, Chien En" sort="Chen, Chien En" uniqKey="Chen C" first="Chien-Jen" last="Chen">Chien-Jen Chen</name><affiliation wicri:level="1"><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Public Health, College of Medicine, National Taiwan, University, Taipei, Taiwan</wicri:regionArea><wicri:noRegion>Taiwan</wicri:noRegion></affiliation></author><author><name sortKey="Liu, Mei Ing" sort="Liu, Mei Ing" uniqKey="Liu M" first="Mei-Ying" last="Liu">Mei-Ying Liu</name><affiliation wicri:level="1"><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Departments of Bacteriology, College of Medicine, National Taiwan, University, Taipei, Taiwan</wicri:regionArea><wicri:noRegion>Taiwan</wicri:noRegion></affiliation></author><author><name sortKey="Cho, Show Ei" sort="Cho, Show Ei" uniqKey="Cho S" first="Show-Mei" last="Cho">Show-Mei Cho</name><affiliation wicri:level="1"><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Departments of Bacteriology, College of Medicine, National Taiwan, University, Taipei, Taiwan</wicri:regionArea><wicri:noRegion>Taiwan</wicri:noRegion></affiliation></author><author><name sortKey="Hsu, Mow Ing" sort="Hsu, Mow Ing" uniqKey="Hsu M" first="Mow-Ming" last="Hsu">Mow-Ming Hsu</name><affiliation wicri:level="1"><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Otolaryngology, College of Medicine, National Taiwan, University, Taipei, Taiwan</wicri:regionArea><wicri:noRegion>Taiwan</wicri:noRegion></affiliation></author><author><name sortKey="Lynn, Tsong Hou" sort="Lynn, Tsong Hou" uniqKey="Lynn T" first="Tsong-Chou" last="Lynn">Tsong-Chou Lynn</name><affiliation wicri:level="1"><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Otolaryngology, College of Medicine, National Taiwan, University, Taipei, Taiwan</wicri:regionArea><wicri:noRegion>Taiwan</wicri:noRegion></affiliation></author><author><name sortKey="Shieh, Ti" sort="Shieh, Ti" uniqKey="Shieh T" first="Ti" last="Shieh">Ti Shieh</name><affiliation wicri:level="1"><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Otolaryngology, College of Medicine, National Taiwan, University, Taipei, Taiwan</wicri:regionArea><wicri:noRegion>Taiwan</wicri:noRegion></affiliation></author><author><name sortKey="Tu, Shieh Ien" sort="Tu, Shieh Ien" uniqKey="Tu S" first="Shieh-Mien" last="Tu">Shieh-Mien Tu</name><affiliation wicri:level="1"><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Otolaryngology, College of Medicine, National Taiwan, University, Taipei, Taiwan</wicri:regionArea><wicri:noRegion>Taiwan</wicri:noRegion></affiliation></author><author><name sortKey="Lee, Hong Sin" sort="Lee, Hong Sin" uniqKey="Lee H" first="Hong-Hsin" last="Lee">Hong-Hsin Lee</name><affiliation wicri:level="1"><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Health, Executive Yuan, Taipei, Taiwan</wicri:regionArea><wicri:noRegion>Taiwan</wicri:noRegion></affiliation></author><author><name sortKey="Kuo, Shiow Ing" sort="Kuo, Shiow Ing" uniqKey="Kuo S" first="Shiow-Ling" last="Kuo">Shiow-Ling Kuo</name><affiliation wicri:level="1"><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Health, Executive Yuan, Taipei, Taiwan</wicri:regionArea><wicri:noRegion>Taiwan</wicri:noRegion></affiliation></author><author><name sortKey="Lai, Ming Ang" sort="Lai, Ming Ang" uniqKey="Lai M" first="Ming-Yang" last="Lai">Ming-Yang Lai</name><affiliation wicri:level="1"><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan, University, Taipei, Taiwan</wicri:regionArea><wicri:noRegion>Taiwan</wicri:noRegion></affiliation></author><author><name sortKey="Hsieh, Chang Ao" sort="Hsieh, Chang Ao" uniqKey="Hsieh C" first="Chang-Yao" last="Hsieh">Chang-Yao Hsieh</name><affiliation wicri:level="1"><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Obstetrics and Gynecology, College of Medicine, National Taiwan, University, Taipei, Taiwan</wicri:regionArea><wicri:noRegion>Taiwan</wicri:noRegion></affiliation></author><author><name sortKey="Hu, Cheng O" sort="Hu, Cheng O" uniqKey="Hu C" first="Cheng-Po" last="Hu">Cheng-Po Hu</name><affiliation wicri:level="1"><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Medical Research, Veterans General Hospital, Executive Yuan, Taipei, Taiwan</wicri:regionArea><wicri:noRegion>Taiwan</wicri:noRegion></affiliation></author><author><name sortKey="Yang, Czau Iung" sort="Yang, Czau Iung" uniqKey="Yang C" first="Czau-Siung" last="Yang">Czau-Siung Yang</name><affiliation wicri:level="1"><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Departments of Bacteriology, College of Medicine, National Taiwan, University, Taipei, Taiwan</wicri:regionArea><wicri:noRegion>Taiwan</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Journal of Medical Virology</title><title level="j" type="abbrev">J. Med. Virol.</title><idno type="ISSN">0146-6615</idno><idno type="eISSN">1096-9071</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>New York</pubPlace><date type="published" when="1987-09">1987-09</date><biblScope unit="volume">23</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="11">11</biblScope><biblScope unit="page" to="21">21</biblScope></imprint><idno type="ISSN">0146-6615</idno></series><idno type="istex">583381D67BFE0CC46E820B7FFE789875F5469C2B</idno><idno type="DOI">10.1002/jmv.1890230103</idno><idno type="ArticleID">JMV1890230103</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0146-6615</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>EBV‐specific DNase antibody</term><term>Epstein‐Barr virus</term><term>nasopharyngeal carcinoma</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Serum samples from 154 patients with nasopharyngeal carcinoma (NPC), 374 with other cancers, 1,000 normal controls from Government Employees' Clinic Center (GECC), and 3,642 individuals of various ethnic‐dialect groups living in high‐risk areas for NPC were collected and the concentration of antibodies to Epstein‐Barr virus (EBV)‐specific DNase activity was determined. Taking a serum sample where 1 ml will neutralize two or more units of the DNase activity as positive, 24 units as low level, 446 units as medium level, and more than 6 units as a high level of antibody, 90.3% of the NPC patients contained significant amounts of antibodies to EBV‐specific DNase activity and most of those had high levels of the antibody. In contrast, only 11% of sera from patients with cancers other than NPC contained antibodies to EBV‐specific DNase activity, and high levels were very rare (2.1%). The difference in positive rates between these two groups is highly significant according to the χ2 test (P < 0.001). The positive rate of this antibody in the control group (GECC) was 5.3% with 0.076, 0.8%, and 4.5% having high, medium, and low levels of antibodies, respectively. Again, the difference in positive rates between the GECC group and the NPC group is statistically significant (P < 0,001). Taken separately, the positive rates of anti‐EBV DNase activity in the three high‐risk groups were 11.7%, 13.0%, and 13.1%. No significant difference in age distribution for the levels of this antibody was observed in the control GECC group or the three high‐risk groups. However, the positive rates of the three high‐risk groups are more than twice those of the GECC group (11.7% ∼ 13.1% vs 5.3%). This ratio coincides with the ratio of the probability of developing NPC in high‐risk groups compared to that of the GECC group (also more than two times). The significance of this coincidence is discussed.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Terre/explor/CobaltMaghrebV1/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001711 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 001711 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Terre
|area= CobaltMaghrebV1
|flux= Main
|étape= Merge
|type= RBID
|clé= ISTEX:583381D67BFE0CC46E820B7FFE789875F5469C2B
|texte= Antibodies to Epstein‐Barr virus‐specific DNase in patients with nasopharyngeal carcinoma and control groups
}}
| This area was generated with Dilib version V0.6.32. |  |